Literature DB >> 21577172

Refractory status epilepticus treated with vagal nerve stimulation: case report.

Brent R O'Neill1, James Valeriano, Andrea Synowiec, Daniel Thielmann, Carole Lane, Jack Wilberger.   

Abstract

BACKGROUND AND IMPORTANCE: Status epilepticus (SE) refractory to medical treatment has a high mortality rate and few effective treatments. CLINICAL
PRESENTATION: We describe the implantation of a vagal nerve stimulator to help terminate a case of refractory SE. A 23-year-old man was in SE for 3 weeks without being able to be weaned from intravenous anesthetic agents. After implantation of a vagal nerve stimulator, SE soon terminated, and the patient could be weaned from sedative agents and made a full recovery.
CONCLUSION: Vagal nerve stimulator should be considered in cases of refractory SE.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21577172     DOI: 10.1227/NEU.0b013e318223b979

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  4 in total

Review 1.  Treatment of Generalized Convulsive Status Epilepticus in Pediatric Patients.

Authors:  Elizabeth L Alford; James W Wheless; Stephanie J Phelps
Journal:  J Pediatr Pharmacol Ther       Date:  2015 Jul-Aug

2.  Vagal Nerve Stimulation in the Treatment of Drug-Resistant Epileptic Encephalopathies in Inborn Errors of Metabolism: Report of 2 Cases.

Authors:  Daniele Grioni; Andrea Landi; Serena Gasperini; Andrea Trezza; Leonardo Fiori; Miriam Rigoldi; Rossella Parini; Erik Pietro Sganzerla
Journal:  Child Neurol Open       Date:  2015-10-25

Review 3.  Updates in Refractory Status Epilepticus.

Authors:  Rohit Marawar; Maysaa Basha; Advait Mahulikar; Aaron Desai; Kushak Suchdev; Aashit Shah
Journal:  Crit Care Res Pract       Date:  2018-05-08

Review 4.  Super-Refractory Status Epilepticus: Prognosis and Recent Advances in Management.

Authors:  Batool F Kirmani; Katherine Au; Lena Ayari; Marita John; Padmashri Shetty; Robert J Delorenzo
Journal:  Aging Dis       Date:  2021-07-01       Impact factor: 6.745

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.